LIMN Stock Chart & Stats
$0.98
--
Market closed
$0.98
--
Day’s Range― - ―
52-Week Range$0.10 - $10.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.43M
Market Cap
$7.21M
Enterprise Value$2.81M
Total Cash (Recent Filing)$1.91M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.92
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding50,607,630
10 Day Avg. Volume1,308,806
30 Day Avg. Volume1,428,866
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-1.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.42K
Enterprise Value/Ebitda-0.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Liminatus Pharma News
LIMN FAQ
What was Liminatus Pharma, Inc.’s price range in the past 12 months?
Liminatus Pharma, Inc. lowest stock price was $0.10 and its highest was $10.20 in the past 12 months.
What is Liminatus Pharma, Inc.’s market cap?
Liminatus Pharma, Inc.’s market cap is $7.21M.
When is Liminatus Pharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Liminatus Pharma, Inc.’s earnings last quarter?
Currently, no data Available
Is Liminatus Pharma, Inc. overvalued?
According to Wall Street analysts Liminatus Pharma, Inc.’s price is currently Overvalued.
Does Liminatus Pharma, Inc. pay dividends?
Liminatus Pharma, Inc. does not currently pay dividends.
What is Liminatus Pharma, Inc.’s EPS estimate?
Liminatus Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Liminatus Pharma, Inc. have?
Liminatus Pharma, Inc. has 50,607,630 shares outstanding.
What happened to Liminatus Pharma, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Liminatus Pharma, Inc.?
Currently, no hedge funds are holding shares in LIMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Liminatus Pharma, Inc.
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Technical Analysis
Compugen
―
Assembly Biosciences
―
Lyell Immunopharma
―
Tenaya Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
―
Insiders
0.21% Mutual Funds
0.69% Other Institutional Investors
98.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---